According to Zacks, “TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York. “
A number of other equities research analysts have also recently weighed in on TGTX. BidaskClub upgraded TG Therapeutics from a buy rating to a strong-buy rating in a research note on Friday, January 10th. HC Wainwright upped their price objective on TG Therapeutics from $20.00 to $24.00 and gave the company a buy rating in a report on Friday, January 17th. Finally, B. Riley initiated coverage on TG Therapeutics in a report on Wednesday, November 27th. They issued a buy rating and a $12.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. TG Therapeutics currently has an average rating of Buy and an average price target of $17.25.
Hedge funds and other institutional investors have recently modified their holdings of the business. California State Teachers Retirement System grew its holdings in TG Therapeutics by 5.6% in the 3rd quarter. California State Teachers Retirement System now owns 127,801 shares of the biopharmaceutical company’s stock valued at $718,000 after buying an additional 6,751 shares in the last quarter. Millennium Management LLC grew its holdings in shares of TG Therapeutics by 6,258.4% during the 3rd quarter. Millennium Management LLC now owns 7,521,910 shares of the biopharmaceutical company’s stock worth $42,235,000 after purchasing an additional 7,403,611 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of TG Therapeutics during the 3rd quarter worth $69,000. Metropolitan Life Insurance Co NY grew its holdings in shares of TG Therapeutics by 53.5% during the 3rd quarter. Metropolitan Life Insurance Co NY now owns 27,289 shares of the biopharmaceutical company’s stock worth $153,000 after purchasing an additional 9,508 shares in the last quarter. Finally, Rhumbline Advisers grew its holdings in shares of TG Therapeutics by 2.1% during the 3rd quarter. Rhumbline Advisers now owns 95,679 shares of the biopharmaceutical company’s stock worth $537,000 after purchasing an additional 1,976 shares in the last quarter. 50.00% of the stock is currently owned by hedge funds and other institutional investors.
About TG Therapeutics
TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.
Further Reading: Initial Coin Offerings entail a high degree of risk
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.